Sodium glucose cotransporter 2 inhibitors (SGLT2I) are a new class of drugs that have been recently FDA-approved for use to lower blood glucose in adults with DM2 given as either monotherapy or as add-on therapy. This evidence concerns the gene SLC5A2 and myotonic dystrophy type 2.